Amneal Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03168L1052

SecurityAMRX / Amneal Pharmaceuticals, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Squarepoint Ops LLC closes position in AMRX / Amneal Pharmaceuticals, Inc.

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 0 shares of Amneal Pharmaceuticals, Inc. (US:AMRX) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 168,633 shares of Amneal Pharmaceuticals, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -100.00 0
2026-02-13 2025-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 168,633 -371,575 -68.78 2,125 -60.72 0.0023
2025-11-14 2025-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 540,208 -32,340 -5.65 5,407 16.76 0.0054
2025-08-27 2025-06-30 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 572,548 420,398 276.30 4,632 263.22 0.0048
2025-08-14 2025-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 572,548 420,398 4,632 0.0048
2025-08-27 2025-03-31 13F/A-1 AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 152,150 27,406 21.97 1,275 29.18 0.0015
2025-05-15 2025-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 152,150 27,406 1,275 0.0015
2025-02-14 2024-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 124,744 105,268 540.50 988 509.26 0.0010
2024-11-14 2024-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 19,476 -91,798 -82.50 162 -77.05 0.0003
2024-08-14 2024-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 111,274 111,274 707 0.0012
2024-02-14 2023-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -31,020 -100.00 0 -100.00
2023-11-14 2023-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 31,020 31,020 131 0.0003
2023-08-14 2023-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -84,308 -100.00 0 -100.00
2023-05-15 2023-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 84,308 61,251 265.65 117 160.00 0.0005
2023-02-14 2022-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 23,057 23,057 46 0.0002
2022-11-14 2022-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -55,303 -100.00 0 -100.00
2022-08-15 2022-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 55,303 -35,305 -38.96 176 -53.44 0.0010
2022-05-16 2022-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 90,608 38,321 73.29 378 51.20 0.0016
2022-02-14 2021-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 52,287 -3,039 -5.49 250 -15.25 0.0007
2021-11-15 2021-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 55,326 -19,273 -25.84 295 -22.77 0.0008
2021-08-16 2021-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 74,599 74,599 382 0.0015
2021-05-17 2021-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -93,034 -100.00 0 -100.00
2021-02-16 2020-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 93,034 -70,723 -43.19 425 -33.07 0.0032
2020-11-16 2020-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 163,757 152,027 1,296.05 635 1,033.93 0.0086
2020-08-14 2020-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 11,730 -26,707 -69.48 56 -58.21 0.0009
2020-05-15 2020-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 38,437 -364,471 -90.46 134 -93.10 0.0034
2020-02-14 2019-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 402,908 -7,095 -1.73 1,942 63.33 0.0116
2019-11-14 2019-09-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 410,003 410,003 1.76 1,189 -38.77 0.0106
2019-08-14 2019-06-30 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 0 -286,808 -100.00 0 -100.00
2019-05-15 2019-03-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 286,808 216,251 306.49 4,064 325.55 0.0430
2019-02-14 2018-12-31 13F AMNEAL PHARMACEUTICALS COM STK CL A 03168L105 70,557 70,557 955 0.0111
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.